Table of Contents Author Guidelines Submit a Manuscript
Contrast Media & Molecular Imaging
Volume 2019, Article ID 4325946, 7 pages
https://doi.org/10.1155/2019/4325946
Research Article

Prognostic Value of 18F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel

1Medical Oncology Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy
2University of Pavia, Ph.D. in Experimental Medicine, Pavia 27100, Italy
3Medical Physics Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy
4Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Milan 20090, Italy
5Nuclear Medicine Research Department, Iason, Graz, Austria
6Nuclear Medicine Department, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic
7Scientific Direction, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy
8Nuclear Medicine Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy
9Nuclear Medicine Unit, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy
10Translational Oncology Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy
11University of Pavia, Department of Internal Medicine, Pavia 27100, Italy

Correspondence should be addressed to E. Quaquarini; ti.ireguamsci@inirauqauq.acire

Received 7 December 2018; Accepted 19 February 2019; Published 26 March 2019

Academic Editor: Gaurav Malviya

Copyright © 2019 E. Quaquarini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, “Global cancer statistics, 2012,” CA: A Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. M. C. S. Wong, W. B. Goggins, H. H. X. Wang et al., “Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries,” European Urology, vol. 70, no. 5, pp. 862–874, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Kirby, C. Hirst, and E. D. Crawford, “Characterising the castration-resistant prostate cancer population: a systematic review,” International Journal of Clinical Practice, vol. 65, no. 11, pp. 1180–1192, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Halabi, C.-Y. Lin, W. K. Kelly et al., “Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer,” Journal of Clinical Oncology, vol. 32, no. 7, pp. 671–677, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. D. A. Loblaw, C. Walker-Dilks, E. Winquist, and S. J. Hotte, “Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review,” Clinical Oncology, vol. 25, no. 7, pp. 406–430, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. A. A. Azad, B. J. Eigl, R. Leibowitz-Amit et al., “Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status,” European Urology, vol. 67, no. 3, pp. 441–447, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. D. L. Suzman, B. Luber, M. T. Schweizer, R. Nadal, and E. S. Antonarakis, “Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone,” The Prostate, vol. 74, no. 13, pp. 1278–1285, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. O. Sartor, R. Coleman, S. Nilsson et al., “Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial,” The Lancet Oncology, vol. 15, no. 7, pp. 738–746, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. K. L. Wallitt, S. R. Khan, S. Dubash, H. H. Tam, S. Khan, and T. D. Barwick, “Clinical PET imaging in prostate cancer,” RadioGraphics, vol. 37, no. 5, pp. 1512–1536, 2017. View at Publisher · View at Google Scholar · View at Scopus
  10. E. E. Parent and D. M. Schuster, “Update on 18F-fluciclovine PET for prostate cancer imaging,” Journal of Nuclear Medicine, vol. 59, no. 5, pp. 733–739, 2018. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Nanni, L. Zanoni, C. Pultrone et al., “18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 43, no. 9, pp. 1601–1610, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. S. M. Schwarzenböck, A. Knieling, M. Souvatzoglou et al., “[11C]choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomy,” Oncotarget, vol. 7, no. 39, pp. 63747–63757, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. S. M. Schwarzenböck, M. Eiber, G. Kundt et al., “Prospective evaluation of [11C]choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 43, no. 12, pp. 2105–2113, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Liu, Z. Chen, T. Wang et al., “Influence of four radiotracers in PET/CT on diagnostic accuracy for prostate cancer: a bivariate random-effects meta-analysis,” Cellular Physiology and Biochemistry, vol. 39, no. 2, pp. 467–480, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. U. De Giorgi, P. Caroli, S. L. Burgio et al., “Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone,” Oncotarget, vol. 5, no. 23, pp. 12448–12458, 2014. View at Publisher · View at Google Scholar
  16. P. Caroli, U. De Giorgi, E. Scarpi et al., “Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 45, no. 3, pp. 348–354, 2018. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Maines, O. Caffo, D. Donner et al., “Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers,” Future Oncology, vol. 12, no. 3, pp. 333–342, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. U. De Giorgi, P. Caroli, E. Scarpi et al., “18F-fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 42, no. 8, pp. 1276–1283, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Soret, S. L. Bacharach, and I. Buvat, “Partial-volume effect in PET tumor imaging,” Journal of Nuclear Medicine, vol. 48, no. 6, pp. 932–945, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. H. I. Scher, M. J. Morris, W. M. Stadler et al., “Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3,” Journal of Clinical Oncology, vol. 34, no. 12, pp. 1402–1418, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. J. H. O, M. A. Lodge, and R. L. Wahl, “Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0,” Radiology, vol. 280, no. 2, pp. 576–584, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Cornford, J. Bellmunt, M. Bolla et al., “EAU-ESTRO-SIOG guidelines on prostate cancer. part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer,” European Urology, vol. 71, no. 4, pp. 630–642, 2017. View at Publisher · View at Google Scholar · View at Scopus
  23. V. Bettinardi, L. Presotto, E. Rapisarda, M. Picchio, L. Gianolli, and M. C. Gilardi, “Physical performance of the new hybrid PET/CT discovery-690,” Medical Physics, vol. 38, no. 10, pp. 5394–5411, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Gallivanone, M. Interlenghi, C. Canervari, and I. Castiglioni, “A fully automatic, threshold-based segmentation method for the estimation of the metabolic tumor volume from PET images: validation on 3D printed anthropomorphic oncological lesions,” Journal of Instrumentation, vol. 11, no. 1, Article ID C01022, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Gallivanone, C. Canevari, L. Gianolli et al., “A partial volume effect correction tailored for 18F-FDG-PET oncological studies,” BioMed Research International, vol. 2013, Article ID 780458, 12 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Gallivanone, C. Canevari, I. Sassi et al., “Partial volume corrected 18F-FDG PET mean standardized uptake value correlates with prognostic factors in breast cancer,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 58, no. 9, pp. 424–439, 2014. View at Google Scholar
  27. O. Caffo, F. Maines, D. Donner, A. Veccia, F. Chierichetti, and E. Galligioni, “Impact of enzalutamide administration on primary prostate cancer volume: a metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients,” Clinical Genitourinary Cancer, vol. 12, no. 5, pp. 312–316, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. S. A. Kwee, J. Lim, A. Watanabe, K. Kromer-Baker, and M. N. Coel, “Prognosis related to metastatic burden measured by 18F-fluorocholine PET/CT in castration-resistant prostate cancer,” Journal of Nuclear Medicine, vol. 55, no. 6, pp. 905–910, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Ceci, P. Castellucci, T. Graziani et al., “11C-choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 43, no. 1, pp. 84–91, 2015. View at Publisher · View at Google Scholar · View at Scopus